Enhanced Dosage Forms of Tissue Kallikrein 1 for Ischemic Conditions
Legal Citation
Summary of the Inventive Concept
Improved dosage forms and systems for treating ischemic conditions using tissue kallikrein 1 polypeptides, offering enhanced efficacy, convenience, and personalized treatment.
Background and Problem Solved
The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions. However, the patent's limitations include the need for precise dosing, real-time monitoring, and tailored treatment approaches. The new inventive concept addresses these limitations by introducing advanced systems and dosage forms that provide precise dosing, real-time monitoring, and personalized treatment.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for treating ischemic conditions, including a portable injector programmed to deliver precise doses of KLK1 polypeptides based on a subject's physiological response. The system also includes a method for optimizing the dosage of KLK1 polypeptides in real-time, a sustained-release matrix for maintaining a therapeutically effective serum level, and a kit for personalized treatment. The kit includes a dosage form, a portable injector, and a monitoring device for tracking the subject's physiological response.
Novelty and Inventive Step
The new claims introduce novel elements, such as the portable injector, real-time monitoring, and sustained-release matrix, which are not present in the original patent. These elements provide a non-obvious solution to the limitations of the original patent, enabling more effective, convenient, and personalized treatment of ischemic conditions.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include variations in the portable injector design, different types of monitoring devices, and alternative sustained-release matrices. Additionally, the kit could be tailored to specific ischemic conditions, such as cardiac ischemia or limb ischemia.
Potential Commercial Applications and Market
The enhanced dosage forms and systems for treating ischemic conditions have significant commercial potential in the pharmaceutical and biotechnology industries. The target market includes hospitals, clinics, and medical research institutions, as well as patients suffering from ischemic conditions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/4853 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K45/06 |
| C | C12 | C12Y304/21035 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically drug delivery systems for protein therapeutics, with expertise in tissue kallikrein 1 (KLK1) polypeptide formulations and methods of treating ischemic conditions
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with advanced degrees, experience in protein drug delivery, knowledge of personalized medicine technologies, and familiarity with injectable drug formulation techniques
Obviousness Rationale
A person having ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core technology, applying known personalized medicine and drug delivery techniques to the existing KLK1 treatment method. The proposed system integrates standard biomedical engineering approaches like real-time monitoring, adaptive dosing, and sustained-release matrices with the existing therapeutic framework. These modifications represent incremental improvements using well-established techniques in drug delivery and personalized treatment strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,608 |
|---|---|
| Title | Dosage forms of tissue kallikrein 1 |
| Assignee(s) | DiaMedica Inc. |